Under 10% of people eligible to benefit from weight-loss injections including Wegovy can access them, states the WHO as it releases its initial guidance on the medications.
Given over a billion individuals worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.
Based on forecasts, more than two billion are projected to be obese by 2030 without intervention.
"The latest guidelines acknowledges that excess weight is a long-term condition that can be managed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant obstacles to universal access to the treatments that can aid individuals in losing significant body mass, explains the body.
GLP-1 Therapy Supply Crisis
Despite the current best projected scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of those who need them, according to the WHO.
The advice urges countries and companies to expand availability, by approaches including licensing agreements.
The intellectual property rights on a key compound – the core component of a leading brand – is set to lapse in a number of nations in 2026.
The Way Obesity Drugs Operate
These medications imitate a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so individuals eat less.
People usually start to lose weight in the initial weeks of beginning the regular doses.
Studies indicates patients may regain a significant portion after a year of stopping the treatment, because their typical hunger come back.
To be carrying excess weight increases your likelihood for contracting health problems, including type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
